Kendra D. Tutsch - Concepedia

Author

Kendra D. Tutsch

University of Wisconsin–Madison

Also Known As

K D Tutsch, K Tutsch, Kendra D Tutsch, Kendra D. Tutsch, Kendra Tutsch

Publications

1.8K

Citations

H-Index

Concepts

All Affiliations

University of Wisconsin–Madison University of Wisconsin Carbone Cancer Center Spanish Oncology Genitourinary Group University of Wisconsin System Regional Cancer Center

About

Kendra D. Tutsch is an author at University of Wisconsin–Madison specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	25	1.2K
2	Health Sciences	5	5	324
3	Gastroenterology	2	2	69
4	Public Health	1	1	51
5	Chemistry	1	1	45

Kendra D. Tutsch

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
Phase I Pharmacokinetic and Pharmacodynamic Study of Recombinant Human Endostatin in Patients With Advanced Solid Tumors James P. Thomas, Rhoda Arzoomanian, Dona Alberti, Journal of Clinical Oncology	2003	226
A Phase I Trial of Perifosine (NSC 639966) on a Loading Dose/Maintenance Dose Schedule in Patients with Advanced Cancer Lynn Van Ummersen, Kim Binger, Jennifer Volkman, Clinical Cancer Research	2004	157
Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Russell F. Jacoby, Carolyn E. Cole, Kendra D. Tutsch, PubMed Tumor BiologyChemoprevention StrategySelective Cox-2 InhibitionGastrointestinal OncologyMedicine	2000	152
Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol James P. Thomas, Kendra D. Tutsch, James F. Cleary, Cancer Chemotherapy and Pharmacology Therapeutic Drug MonitoringPharmacologyPharmacokinetic TrialPharmacotherapyMedicine	2002	122
Phase I clinical trial of perillyl alcohol administered daily. Gregory H. Ripple, Michael N. Gould, James A. Stewart, PubMed Substance UseChemoprevention StrategyPathologyPharmacotherapyOvarian Cancer	1998	116
Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day. Gregory H. Ripple, Michael N. Gould, Rhoda Arzoomanian, PubMed Chemoprevention StrategyPharmacokinetic StudyPharmacotherapyAlcohol MisusePharmacological Study	2000	106
Phase I clinical trial and pharmacokinetics of carboplatin (nsc 241240) by single monthly 30-minute infusion Jim M. Koeller, Donald L. Trump, Kendra D. Tutsch, Cancer ThrombopoiesisHematological MalignancyTranslational MedicineUrologyOncology	1986	88
Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer Howard H. Bailey, Steven Attia, Richard R. Love, Cancer Chemotherapy and Pharmacology Breast OncologyOncologyPhase Ii TrialMedicineCancer Management	2007	66
A Phase I and Pharmacologic Trial of Two Schedules of the Proteasome Inhibitor, PS-341 (Bortezomib, Velcade), in Patients with Advanced Cancer Grace K. Dy, James P. Thomas, George Wilding, Clinical Cancer Research	2005	66
Improvement in the therapeutic index of cisplatin (NSC 119875) by pharmacologically induced chloruresis in the rat. Robert H. Earhart, Patricia Martín, Kendra D. Tutsch, PubMed Electrolyte DisorderRenal PathologyMolecular PharmacologyRenal FunctionElectrolyte Disturbance	1983	64

Page 1